Tocilizumab vs Standard Care on Preventing Worsening in Patients Hospitalized With COVID-19 Pneumonia

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 1 P.M. (ET), TUESDAY, OCTOBER 20, 2020

Media advisory: The full study and editorial are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.6615?guestAccessKey=05e037ab-d891-4213-b298-6b97f63fd8f7&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102020

 

What The Study Did: Researchers in this randomized clinical trial compared the effect of early administration of tocilizumab with standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia.

Authors: Carlo Salvarani, M.D., of Unita Operativa di Reumatologia in Reggio Emilia, Italy, is the corresponding author.

 

Visual Abstract

(doi:10.1001/jamainternmed.2020.6615)

 

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.